The Western diet is associated with gastrointestinal dysbiosis, an active contributor to the pathophysiology of obesity and its comorbidities. Gastrointestinal dysbiosis is strongly linked to increased adiposity, low-grade inflammation, dyslipidaemia, and insulin resistance in individuals with morbid obesity. Bariatric bypass surgery remains the most effective treatment for achieving significant weight loss and alleviating obesity-related comorbidities. A growing body of evidence indicates that traditional Roux-en-Y Gastric Bypass (RYGB) improves the disrupted gut microbiota linked with obesity, potentially contributing to sustained weight loss and reduction of comorbidities. One Anastomosis Gastric Bypass (OAGB), a relatively new and technically simpler bariatric procedure, has shown both safety and efficacy in promoting weight loss and improving comorbidities. Few studies have investigated the impact of OAGB on gut microbiota. This review provides insights into the pathogenesis of obesity, current treatment strategies and our current understanding of the gut microbiota in health and disease, including modulating the gut microbiota as a promising and novel way to alleviate the burden of obesity and cardiometabolic conditions. By exploring the impact of gastric bypass surgery on gut microbiota-host interactions, we aim to shed light on this evolving field of research and uncover potential therapeutic targets for elevating outcomes in bariatric surgery.

中文翻译：

---

胃旁路减肥手术对病态肥胖患者肠道菌群的影响。


西方饮食与胃肠道菌群失调有关，胃肠道菌群失调是导致肥胖及其合并症病理生理学的积极因素。胃肠道菌群失调与病态肥胖个体的肥胖增加、低度炎症、血脂异常和胰岛素抵抗密切相关。减重搭桥手术仍然是实现显着体重减轻和缓解肥胖相关合并症的最有效治疗方法。越来越多的证据表明，传统的 Roux-en-Y 胃旁路术 （RYGB） 可改善与肥胖相关的肠道微生物群被破坏，可能有助于持续减轻体重和减少合并症。一种吻合胃旁路术 （OAGB） 是一种相对较新且技术更简单的减肥手术，在促进体重减轻和改善合并症方面已显示出安全性和有效性。很少有研究调查 OAGB 对肠道微生物群的影响。这篇综述提供了对肥胖发病机制、当前治疗策略以及我们目前对健康和疾病中肠道微生物群的理解的见解，包括调节肠道微生物群作为减轻肥胖和心脏代谢疾病负担的一种有前途的新型方法。通过探索胃旁路手术对肠道微生物群-宿主相互作用的影响，我们的目标是阐明这一不断发展的研究领域，并发现提高减肥手术结果的潜在治疗靶点。